Drugs / Neosil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03659201 | Sep 2018 → Jun 2019 | telogen effluvium | EMS | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neosil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03659201 ↗ |
| Route | Oral | “2 tablets of Neosil Oral, per day - during the 12 weeks.” NCT03659201 ↗ |